throbber
§
`
`Lu
`H
`>
`
`
`
`._l
`<
`U
`H
`O
`O
`1—]
`O
`U
`
`Q1
`
`1521-0031:“121'6403-533- 520552530
`Pl-IARMACOLOGICAI. REVIEWS
`Copyright 0 2012 by The American Societ}f for Pharmacology and Experimental Therapeutics
`Pharmomt Rev 64:583-620. 2012
`
`Vol. 64, No. 3
`55878771667
`
`ASSOClATE EDITOR: CLIVE PAGE
`
`The Pharmacological Treatment of Pulmonary
`Arterial Hypertension
`
`Ly'n R. Frurnkin
`
`DepartmentofChemicalandSystemsBiotogy,StanfordUniversitySchoolofMedicine,Stanford,California
`
`Abstract ................................................................................ 584
`I. Introduction ............................................................................ 584
`11. Current treatment options ............................................................... 586
`A. History of product approvals .......................................................... 586
`1. Epoprostenol ...................................................................... 586
`2. Treprostinil ....................................................................... 586
`3. Iloprost ........................................................................... 587
`4. Bosentan ......................................................................... 587
`5. Ambrisentan ...................................................................... 588
`6. Nitric oxide ....................................................................... 588
`7. Sildenafil ......................................................................... 589
`8. Tadalafil ......................................................................... 589
`B. Additional therapies and approaches ................................................... 589
`C. Approved drugs ...................................................................... 589
`1. Epoprostenol ...................................................................... 589
`a. Mechanism of action ............................................................ 589
`13. Clinical studies ................................................................. 590
`c. Special considerations........................................................... 591
`d. Commercial considerations ...................................................... 591
`2. Treprostinil ....................................................................... 592
`a. Mechanism of action ............................................................ 592
`1). Clinical studies (subcutaneous infiision) .......................................... 592
`c. Clinical studies {intravenous infusion) ............................................ 593
`d. Clinical studies (inhalation) ..................................................... 594
`e. Oral treprostinil ................................................................ 594
`f Commercial considerations ...................................................... 595
`
`3. Iloprost ........................................................................... 596
`a Mechanism of action ............................................................ 596
`5. Clinical studies ................................................................. 596
`c. Commercial considerations ...................................................... 596
`4. Bosentan ......................................................................... 597
`a. Mechanism of action ............................................................ 597
`13. Clinical studies ................................................................. 597
`
`c. Expansion of product label ....................................................... 598
`d. Commercial considerations ...................................................... 599
`e. Additional pulmonary arterial hypertension and pulmonary hypertension
`populations .................................................................... 600
`f. Additional study populations .................................................... 601
`5. Ambrisentan ...................................................................... 601
`a. Clinical studies ................................................................. 601
`b. Commercial considerations ...................................................... 603
`
`Address correspondence to: Dr. Lyn Frumkin, 2543 11'2 56th Ave. SW, Seattle, WA 98116. E—mail: lfrumkin@stanford.edu
`This article is available online at httpifi'pharmrevaspetjoumalsorg.
`http::’fdx.doi.orgf10.1124tpr.111.005587.
`
`583
`
`WATSON LABORATORIES v. UNITED THERAPEUTICS, |PR2017—01622
`
`UNITED THERAPEUTICS, EX. 2069
`
`Page 1 of 38
`
`
`
`“oz‘52;umewuoisanfiliqmoi;papeolumoa
`
`
`
`
`
`

`

`584
`
`FRU'MKIN
`
`6. Sitaxentan ........................................................................ 603
`a. Withdrawn from market ........................................................ 603
`7. Nitric oxide ....................................................................... 603
`a. Mechanism of action ............................................................ 603
`b. Clinical studies ................................................................. 603
`8. Sildenafil ......................................................................... 604
`a. Mechanism of action ............................................................ 604
`b. Clinical studies ................................................................. 604
`
`c. Long—term follow-up ............................................................ 605
`(1. Label expansion. ............................................................... 605
`e. Commercial considerations ...................................................... 606
`9. Tadalafil ......................................................................... 607
`a. Clinical studies ................................................................. 607
`
`b. Longnterm follow-up ............................................................ 608
`c. Commercial considerations ...................................................... 608
`
`III. Drugs in late-stage development .......................................................... 608
`A. Tyrosine kinase inhibitor (imatinib) .................................................... 608
`B. Soluble guanylate cyclase stimulator (riociguatl ......................................... 609
`C. Nonprostanoid prostacyclin receptor
`agonist (selexipag) ................................................................... 610
`D. Tissue-targeting endothelin receptor
`antagonist (macitentan) ............................................................... 610
`E. Serotonin transport inhibitor (escitalopram) ............................................ 611
`F. Serotonin receptor antagonist (terguride) ............................................... 611
`G. Prostacyclin analog (beraprost—modified release) ......................................... 611
`H. Endothelial nitric oxide synthase (cicletanine) ........................................... 614
`I. Gene therapy with progenitor endothelial cells .......................................... 614
`IV. Comparison of approved therapies ........................................................ 614
`V. Conclusion .............................................................................. 615
`
`Acknowledgments ....................................................................... 615
`References .............................................................................. 615
`
`Abstract—Pulmonary arterial hypertension (PAH)
`is a life-threatening and progressive disease of various
`origins characterized by pulmonary vascular remodel-
`ing that leads to increased pulmonary vascular resis-
`tance and pulmonary arterial pressure, most often re-
`sulting in right-sided heart failure. The most common
`symptom at presentation is breathlessness, with im-
`paired exercise capacity as a hallmark of the disease.
`Advances in understanding the pathobiology over the
`last 2 decades have led to therapies {endothelin receptor
`antagonists, phosphodiesterase type 5 inhibitors, and
`prostacyclins or analogs) initially directed at reversing
`
`the pulmonary vasoconstriction and more recently di-
`rected toward reversing endothelial cell dysfunction
`and smooth muscle cell proliferation. Despite these ad-
`vances, disease progression is common even with use of
`combination regimens targeting multiple mechanistic
`pathways. Overall 5-year survival for PAH has increased
`significantly from approximately 30% in the 19805 to
`approxin1ately 60% at present, yet remains abysmal.
`This review summarizes the mechanisms of action, clin-
`ical data, and regulatory histories of approved PAH
`therapies and describes the latest agents in late-stage
`clinical development.
`
`I. Introduction
`
`Pulmonary arterial hypertension (PAH‘) is a progres-
`sive disease characterized by increased pulmonary vas-
`
`lAbbreviations: 5—HT, 5—hydroxytryptamine (serotonin); AWP, av—
`erage wholesale price; CI, confidence interval; CML, chronic myelog—
`enous leukemia; COPD, chronic obstructive pulmonary disease;
`CTEPH, chronic thromboembolic pulmonary hypertension; EMA,
`European Medicines Agency; EPC, endothelial progenitor cell; ERA,
`endothelin receptor antagonist; ET, endothelin; EU, European
`Union; FDA, US. Food and Drug Administration; mPAP, mean
`pulmonary artery pressure; NAION. nonarteritic anterior ischemic
`
`cular resistance, leading to chronic elevation in pulmo-
`nary arterial pressure resulting fiom restricted flow
`through the pulmonary arterial circulation. These
`pathobiological features typically lead to right-sided
`
`optic neuropathy; NYHA, New York Heart Association; P450, cyto-
`chrome P450; PAH, pulmonary arterial hypertension; PDE, phos—
`phodiesterase; PDGF, platelet-derived growth factor; PDGF-R,
`platelet—derived growth factor receptor; PH, pulmonary hyperten—
`sion; PPHN, persistent pulmonary hypertension of the newborn;
`prostacyclin, prostaglandin IQ; PVR, pulmonary vascular resistance;
`WHO, World Health Organization.
`
`UNITED THERAPEUTICS, EX. 2069
`
`WATSON LABORATORIES V. UNITED THERAPEUTICS, |PR2017—01622
`
`Page 2 of 38
`
`

`

`TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
`
`585
`
`heart failure and premature death (Barst et al., 2004b;
`Galié et al., 2009b). No large-scale epidemiological stud-
`ies evaluating the prevalence of PAH have been pub-
`lished, but several registries in the United States and
`Europe suggest that the prevalence of PAH in adults is
`approximately 12 to 50 per million people {Humbert et
`al., 2006; Peacock et al., 2007; Frost et al., 2011}. This
`figure may be an underestimation given continued ad-
`vances in the diagnosis of the disease. The Registry to
`EValuate Early And Long-term pulmonary arterial hy-
`pertension (REVEAL) is the largest registry of PAH
`reported to date, with 2525 US. adults meeting tradi-
`tional hemodynamic criteria; mean age at diagnosis was
`50 years with a fournto-one female predominance (Ba-
`desch et al., 2010).
`The current classification of pulmonary hyperten-
`sion (PH) has group 1 synonymous with PAH and its
`subcategories (Table 1) (Simonneau et al., 2009). Id-
`iopathic PAH occurs in the absence of known risk
`factors and is the most common form of the disease
`
`(Galié et al., 2009b; Badesch et al., 2010). Figure 1
`shows the distribution of additional subcategories of
`PAH reported from REVEAL, which includes a familial
`form (now termed heritable), a form attributable to
`drugs and texins, and forms in association with connec-
`tive tissue diseases, congenital heart diseases, HIV in-
`fection, portal hypertension, and other systemic condi-
`tions (Badesch et al., 2010).
`PAH is a lethal disease. The median period of survival
`after diagnosis, based on an early U.S. National Insti-
`tutes of Health Registry with prospective follow-up, was
`less than 3 years for 194 untreated patients with idio-
`pathic or heritable PAH (formerly called primary pul-
`monary hypertension) with a mean age of 36 years (Rich
`et al., 1987; D’Aionzo et al., 1991). At present, average
`survival after diagnosis in adults is estimated at 5 to 7
`years (Gomberg-Maitland et al., 2011; Kane et al., 2011;
`Benza et al., 2012), with a similarly poor overall prog-
`nosis in children (Barst et al., 2011a).
`The pathobiology of PAH is poorly understood but
`includes pathologic changes in the intima, media, and
`adventitial layers of the vascular wall. Both vascular
`endothelial and smooth muscle cells have characteristics
`
`of abnormal growth, with excess cellular proliferation
`and apoptosis resistance (Fig. 2). These abnormalities in
`resident vascular cells, in combination with inflamma-
`tion, excess vasoconstriction, and in situ thrombosis,
`contribute to physical narrowing of the distal pulmonary
`arterioles. This narrowing causes a dramatic increase in
`pulmonary vascular resistance, which leads to the
`chronic and progressive elevation of pulmonary arterial
`pressure. Odd clusters of immature blood vessels with
`endothelial cell proliferation (called plexiform lesions)
`are also characteristic Pathologic abnormalities in PAH
`and are not found in diseases of the systemic circulation
`(Rabinovitch 2007).
`
`TABLE 1
`Current clinicalI classification ofpnimonaiy hypertension from the 4th
`World Symposium on Pulmonary Hypertension. (Dana Point, CA. 2008)
`[Reprinted from Simonneau G. Robbins IM, Bcghetti M, Channiek RN. Delcmix M,
`Danton CP, Elliott CG, Gains SP, Gladwin MT, Jing ZC, Krowka MJ. Langleben D,
`Nakanishi N, and Sousa R (2009} Updated clinical classification of pulmonary
`hypertension. J Am Coil Cordial 54:343-354. Copyrigth 2009 Elsevier. Used with
`permission]
`
`1. Group 1 pulmonary arterial hypertension (PAH)
`1.1. Idiopathic PAH
`1.2. Heritable
`1.2.1. BMPR2
`1.2.2. ALKl, endoglin (with or without hereditary
`hemorrhagic telangiectasia)
`1.2.3. Unknown
`1.3. Drug— and toxin—induced
`1.4. Associated with
`1.4.1. Connective tissue diseases
`1.4.2. HIV infection
`1.4.3. Portal hypertension
`1.4.4. Congenital heart diseases
`1.4.5. Schistosomiasis
`1.4.6. Chronic hemolytic anemia
`1.5 Persistent pulmonary hypertension of the newborn
`1'. Pulmonary veno-occlusive disease (PVOD) andfor pulmonary
`capillary hemangiomatosis (PCH)
`2. Group 2 pulmonary hypertension owing to left heart disease
`2.1. Systolic dysfunction
`2.2. Diastolic dysfunction
`2.3. Valvular disease
`3. Group 3 pulmonary hypertension owing to lung diseases andfor
`hypoxia
`3.1. Chronic obstructive pulmonary disease
`3.2, Interstitial lung disease
`3.3. Other pulmonary diseases with mixed restrictive and
`obstructive pattern
`3.4. Sleep-disordered breathing
`3.5. Alveolar hypoventilation disorders
`3.6. Chronic exposure to high altitude
`3?. Developmental abnormalities
`4. Group 4 chronic thromboernbolic pulmonary hypertension
`(CTEPH)
`5. Group 5 pulmonary hypertension with unclear multifactorial
`mechanisms
`5.1, Hematologic disorders: myeloproliferative disorders,
`splenectomy
`5.2. Systemic disorders: sarcoidosis, pulmonary Langerhans cell
`histiocy'tosis: lymphangioleiomyomatosis,
`neurofibromatosis, vasculitis
`5.3. Metabolic disorders: glycogen storage disease, Gaucher
`disease, thyroid disorders
`5.4. Others: tumoral obstruction, fibrosing mediastinitis,
`chronic renal failure on dialysis
`ALKI, activin receptor-like kinase type i: BMPRZ, bone momhogenctie protein
`receptor type ‘2.
`
`Therapies for PAH target the prostacyclin, endothe-
`lin, or nitric oxide (NO) pathways and are believed to be
`efficacious by reversing or diminishing vasoconstriction,
`vascular endothelial cell proliferation, smooth muscle
`cell proliferation, and endothelial dysfunction (Boutet et
`al., 2008; McGoon and Kane, 2009). For example, pros-
`tacyclins are potent vasodilators that can also inhibit
`vascular smooth muscle growth. PAH is associated with
`reduced pulmonary levels of prostacyclin as a result of
`underexpression of endothelial prostacyclin synthase.
`Endothelin receptor antagonists (ERAS) block the effect
`of endothelin, a potent endogenous vasoconstrictor and
`mitogen, at smooth muscle cell receptors. Phosphodies-
`
`UNITED THERAPEUTICS, EX. 2069
`
`WATSON LABORATORIES V. UNITED THERAPEUTICS, |PR2017—01622
`
`Page 3 of 38
`
`

`

`586
`
`A
`
`PPHN
`U.
`onow0.4%
`
`
`
`
`
`FRUMKJN
`
`01h er
`
`PCH
`<0.1%
`FPAH
`2.7%
`
`_
`
`
`
`FIG. 1. World Health Organization (WHO) group 1 PAH classification of REVEAL (U.S. Registry) patients at enrollment. A, WHO group 1
`classification. B, breakdown of associated PAH (APAH) subgroup. The most current classification revised the category of familial PAH (FPAH) used
`at the time of the REVEAL registryr to heritable PAH to reflect advances in identifying familial cases with and without gerniline mutations (Simonneau
`et al_, 2009) (Table I). CHD, congenital heart disease; CVDICTD, collagen vascular diseaselconnective tissue disease; HT, hypertension; IPAH,
`idiopathic PAH; PCH, pulmonary capillary hemangiomatosis; PVOD, pulmonary vcnoocclusivc disease. IReprinted from Badcsch DB, Raskob GE,
`Elliott CG. Krichman AM. Farbcr HW, Frost AB, Barst RJ, Benza RL, Liou TG, Turner M, et al. (2010) Pulmonary arterial hypertension: baseline
`characteristics from the REVEAL Registry. Chest 137:376—387. Copyright © 2010 American College of Chest Physicians. Used with permission]
`
`terase type 5 (PDE-5) inhibitors facilitate vasodilation
`by promoting the activity of the nitric oxide pathway by
`inhibiting degradation of cGMP, a second messenger
`that prompts relaxation of vascular smooth muscle. New
`therapies under development target these and addi
`tional pathways.
`
`11. Current Treatment Options
`
`A. History of Product Approvals
`
`Approved drugs currently used in the treatment of
`PAH in North America or the European Union (EU)
`include the orally administered PDE-5 inhibitors silde-
`nafil (Revatio) and tadalafil (Adcirca), the dual ERA
`bosentan (Tracleer), and the selective endothelin-1A re-
`ceptor antagonist ambrisentan [Letairis (United States)!
`Volibris (internationalfl. Patients with more advanced
`disease are often treated with prostacyclins or prostacy—
`clin analogs such as iloprost (Ventavis) or treprostinil
`(Tyvaso) given as multiple daily inhalations, epopros-
`tenol (Flolaaneletri) or treprostinil (Remodulin) given
`as continuous intravenous infusions, or treprostinil also
`used as a continuous subcutaneous infusion. Intrave-
`
`nous injection of sildenafil is approved for patients who
`are currently prescribed but are temporarily unable to
`take oral sildenafil. Inhaled nitric oxide (INOmax) is
`approved for the neonatal form of PAH—persistent pul-
`monary hypertension of the newborn (PPHN).
`This section briefly reviews the route of administra-
`tion, mechanism of action, and approval histories of 8
`drugs (including their different formulations) that tar-
`get the prostacyclin (epoprostenol, iloprost, treprostinil),
`endothelin (bosentan, ambrisentan), and nitric oxide
`(tadalafil, sildenafil, NO) pathways and are currently
`used in the treatment of PAH in North America or the
`
`and Drug Administration (FDA) approved epoprostenol
`in 1995 for use as a continuous intravenous treatment
`
`for patients with World Health Organization (WHO)
`functional classes III (moderate) and IV (severe) symp-
`toms and for primary pulmonary hypertension that does
`not respond adequately to conventional therapy. Subse-
`quent label revisions have included the addition of pa-
`tients with PAH related to scleroderma (2000) and all
`
`patients with PAH (PH group 1) regardless of etiology to
`impmve exercise capacity (2011).
`Epoprostenol reduces morbidity and improves surviv-
`al; the latter has been demonstrated mainly in those
`with idiopathic PAH in a pivotal controlled trial (com-
`paring conventional therapy) and in open-label, obser-
`vational studies that have also included other subgroups
`of PAH. Adverse events are primarily related to its con-
`tinuous intravenous delivery system and include jaw
`pain, nausea, and diarrhea, with potentially serious,
`life-threatening complications such as bloodstream in-
`fections, sepsis, thromboembolic events, and inadvertent
`drug interruption. With the availability of other thera-
`pies, epoprostenol is most often reserved for patients
`with advanced symptoms who do not adequately im-
`prove on oral or inhaled drugs. It is unusual for a patient
`to be awaiting transplantation without receiving epopro-
`stenol. Epoprostenol is available in over 20 countries,
`including the United States, Canada, Japan, Australia,
`and select regions in Europe. The patent for epopros-
`tenol expired in 2007. In 2008, the FDA approved both
`the first generic version of epoprostenol and a new in-
`travenous formulation (i.e., Veletri) that is more stable
`at room temperature.
`2. Treprostinil. Treprostinil is a prostacyclin analog
`administered as a continuous subcutaneous or intrave-
`
`EU (Fig. 3). The drugs are reviewed in more detail in
`subsequent sections.
`1. Epoprostenol. Epoprostenol, which requires con-
`tinuous infusion through a central venous catheter and
`infusion pump, is synthetic prostacyclin. The US. Food
`
`nous infusion (Remodulin) or by inhalation (Tyvaso).
`The FDA (and Health Canada) approved treprostinil
`given subcutaneously in 2002 for the relief of symptoms
`associated with exercise in patients with PAH in New
`York Heart Association (NYHA) functional classes II to
`
`WATSON LABORATORIES V. UNITED THERAPEUTICS, |PR2017—01622
`
`UNITED THERAPEUTICS, EX. 2069
`
`Page 4 of 38
`
`

`

`TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
`
`587
`
`® RISK FACTORS AND
`ASSOCIATED conomous
`
`Collagen Vascular Plsoasa
`Ella! H“! :WMIDISGBBG
`you
`n
`HN Inlaction
`_
`Drugs and Towns
`Pnegnancy
`
`SU SCEPTIBILITY
`Abnormal BMW? Gene
`Other Genet-t: Fac1ors
`
`@vnseumn INJURY —b— O DISEASE Pnoonsssmu
`Loss at Response to Short-Acting
`End-othelial Dyslunoliun
`Vamilator Trial
`* mm: Oxide Synthase
`thslacyclin PfOULICIIDI'I
`f anomnoxnno Producer!
`'
`tEnacumnn l Pmaucbnn
`_
`Vascular Smooth Muscle Dyslmcuon
`Impaired Willage-Galed
`Potassium Channel [ng
`
`Smocln Muse:
`WW"?
`.
`
`
`
`Muentma anolntlnal
`_.
`;- '
`
`'
`"
`Fi'ulllelstrm~
`I1 5i'.u
`
`Tl'nfl'{)¢$l$\
`
`Ploucvm
`
`Leann _
`
`Easy Humal y
`Proliferolon
`
`
`Sm" Mme
`HmcflrW'V‘
`
`.
`
`
`NORMAL
`
`(A) CONTROL
`
`‘2. Characteristic pathological features of PAH. Top, diagram showing progression to vasoconstriction (and related smooth muscle hypertro-
`FIG.
`phy}, vascular cell proliferation, and thrombosis in situ. [Reprinted from Gaine S [2000! Pulmonary hypertension. JAMA 284:3160 —3168. Copyright
`© 2000 American Medical Association. Used with permission.| Bottom. representative optical coherence tomography images of distal pulmonary
`arteries with comparable luminal areas for patient with normal pulmonary arteryr pressure EA] and patient with idiopathic PAH diagnosed 5 years
`earlier EB), showing vascular intima and media nearly twice the thickness [0.28 versus 0.16 mm}. Scale bar. 1.0 mm. Courtesy of Dr. Yoshihirn
`Fukumoto [Tohoku University. Sendai, Japan].
`
`IV (mild to severe symptoms}. Treprostinil was subse-
`quently launched in most of Europe, Canada, and other
`regions. Infusion site pain and reactions are the most
`common adverse events with subcutaneous treprostinil;
`these events are reported in more than 80% of patients
`but wane over time in many (Galié et al., 2009b). In
`2004, on the basis of data establishing bioequivalence,
`the FDA approved an intravenous formulation of trepro-
`stinil for patients with PAH in functional classes II to IV
`who do not tolerate the subcutaneous form or in whom
`
`intravenous administration may be preferable to subcu-
`taneous infusion. In early 2006, the FDA expanded the
`intravenous Remodulin label
`to include patients in
`whom transition from epoprostenol may provide a better
`overall quality of life because of its temperature stability
`and longer half-life. In 2009, an inhaled form of trepro-
`stinil was approved in the United States to improve
`
`exercise capacity in patients with PAH in functional
`class III (moderate), with recommended four times daily
`dosing.
`Iloprost is a prostacyclin analog initially
`3. Repeat.
`approved as an aerosolized form in the EU and Australia
`(in 2003} for patients with idiopathic PAH and func—
`tional class III status, and in the United States (in 2004)
`for patients with PAH and functional class III (moderate)
`or IV (severe) symptoms. Iloprost was later launched in
`additional regions. Iloprost is generally well tolerated, al-
`though a significant limitation is its short elimination half-
`life (20 —25 min), with recommended dosingr of six to nine
`times daily. The most frequent adverse events are cOugh,
`headache, and flushing.
`4. Bosenton. Bosentan is a dual—endothelin {ET-1M3)
`receptor antagonist that was initially approved by the
`FDA in 2001 to improve exercise ability and decrease the
`
`WATSON LABORATORIES V. UNITED TH ERAPEUTICS, |PR2017-01622
`
`UNITED THERAPEUTICS, EX. 2069
`
`Page 5 of 38
`
`

`

`588
`
`FRUMKJN
`
`bosentan Idual ERA] approved as oral
`agent by FDA for PAH with moderate
`or severe functional class symptoms
`2001
`
`epoprostenol (synthetic prostacyclin}
`approved by FDA as continuous
`N infusion for primary pulmonary
`hypertension with moderate or severe
`functional class symptoms
`
`1995
`
`Iloprost [prostacyclln analogue]
`approved in EU for inhalation in
`those with idiopathic m” and
`moderate functional class symptoms
`
`2003
`
`Sildenafi {PDE-S inhibitor)
`approved by FDA as oral agent for
`PAH {PH Group I}
`
`2005
`
`epoprostenol approved by FDA as new formulation
`for continuous N infusion that is more stable at room
`temperature and can be retrigerateci longer in advance of
`use. approved for primary pulmonary hypertension or
`PAH associated with the scleroderma spectmm of disease in
`those with moderate or severe functional class symptoms
`2008
`
`2010
`1990
`
`
`1999
`nitric oxide approved by FDA as
`inhaled agent for term and nearterm
`l> 3-i weeks} neonates with hypoxic
`respiratory failure associated with PH
`
`2004
`
`treprostinil approved by FDA as continuous
`N infusion for those with PAH and mild to
`severe functional class symptoms (who are
`unable to tolerate 5.c infusion]
`
`2009
`MAY
`tadalafi [P DE-S inhibitor} approved by FDA
`as oral agent for PAH (PH Group 1)
`JUL Y
`treprosrinil {inhaled} approved by FDA for
`those with PAH {PH Group 1} and moderate
`functional class symptoms
`MOMII
`sildenafl approved by FDA as IV bolus
`injection for those with PAH tPH Group 1]
`temporarily unable to take oral form
`
`2002
`treprost'rnil lprostacyclin analogue] approved
`by FDA as continuous s.c. infusion for PAH
`with mild to severe functional class symptoms
`
`200}lr
`ambrisentan (selective ERA] approved by
`FDA as oral agent for PAH {PH Group I} with
`mild or moderate functional class symptoms
`
`FIG. 3. ’I‘imclinc of first approval of drugs [and their different formulations) currently used for PAH in North America or the EU.
`
`rate of clinical worsening in patients with PAH in WHO
`functional classes III and IV. Because of risk of toxicity,
`bosentan is available in the United States only through
`a restricted distribution program that monitors liver
`function enzyme values and pregnancy status on a
`monthly basis. Subsequent approvals have occurred in
`more than 50 regions. In Canada and the EU, the initial
`indication was more restrictive than in the United
`
`States, reflecting the predominant study population en-
`rolled in the pivotal bosentan trial: PAH that is idio-
`pathic or associated with scleroderma and WHO func-
`tional class III symptoms.
`In 2006,
`the label was
`extended in Canada to include patients with either PAH
`related to HIV infection or congenital heart disease
`(functional class III or IV status) and in the EU to
`
`include patients with PAH related to congenital systemic-
`topulmonary shunts or Eisenrnenger syndrome (class III
`status). In the EU (in 2008) and the United States and
`Canada (in 2009), the label was further revised to include
`patients with mild (class II) symptoms. In 2009, the EU
`label was expanded to include a pediatric dispersible for-
`mulation.
`5. Ambrisentan. Ambrisentan is an oral selective
`
`ETA-receptor antagonist approved in the United States
`in 2007. The drug was indicated as a once-daily treat-
`ment for patients with PAH and WHO functional class II
`(mild) or III (moderate) symptoms to improve exercise
`
`capacity and delay clinical worsening. Ambrisentan was
`later approved for use in Canada {in 2008), EU (2008},
`New Zealand (in 2009), Australia (in 2009), and Japan
`(in 2010). A subsequent U.S.
`label revision specified
`treatment of patients with PAH regardless of functional
`status. Ambrisentan was initially dispensed in the
`United States only to patients through a restricted dis-
`tribution program that monitored liver function enzyme
`values and pregnancy status on a monthly basis (as is
`the case with bosentan). In 2011, the FDA removed the
`requirement for monthly monitoring of liver function
`values with ambrisentan as a result of additional data
`
`reporting no significant increase in hepatic toxicity com-
`pared with patients with PAH not receiving an ERA. As
`a result, ambiiaentan requires restricted distribution
`solely for pregnancy monitoring in women of childbearing
`potential because of risk of drug-related teratogenicity.
`6. Nitric Oxide. N0 is a potent pulmonary vasodila-
`tor that can be rapidly delivered to the lung by inhala-
`tion. Nitric oxide (INOmx) for inhalation was approved
`by the FDA in 1999 for term and near-term (older than
`34 weeks’ gestation) neonates with hypoxic respiratory
`failure and PPHN. In 2001, approval in the EU was
`obtained and subsequently expanded to include patients
`with peri- and postoperative PH in conjunction to car-
`diac surgery.
`
`UNITED THERAPEUTICS, EX. 2069
`
`WATSON LABORATORIES V. UNITED THERAPEUTICS, |PR2017—01622
`
`Page 6 of 38
`
`

`

`TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
`
`589
`
`7. Siidenafii. Sildenafil is an oral PDE-5 inhibitor
`initially developed and marketed for erectile dysfunction
`(trade name Viagra). Sildenafil (trade name Revatio)
`was approved in 2005 as a thrice-daily therapy for PAH
`by the FDA and European Medicines Agency (EMA).
`Subsequent approvals have occurred in over 50 coun-
`tries. In the United States, sildenafil is indicated for
`patients with PAH regardless of functional class. In the
`EU, sildenafil use is restricted to the predominant pop-
`ulation studied in the pivotal phase 3 trial: patients with
`PAH that is either idiopathic or associated with connec-
`tive tissue disease in fimctional class 11 (mild) or III
`
`(moderate). Sildenafil is also approved as an intrave-
`nous injection for patients who are temporarily unable
`to take oral sildenafil and in the EU as an oral suspen—
`sion for the treatment of patients with PAH aged 1 to 17
`years.
`
`8. Tadalafii. Tadalafil is also an oral PDE-5 inhibi-
`tor, approved in 2009 in the United States and EU (and
`in 2010 in Canada and Japan) as a once-daily therapy to
`improve exercise capacity in patients with PAH. The EU
`label specifies use in those with mild to moderate func-
`tional class, reflecting the predominant phase 3 pivotal
`study population.
`
`B. Additional Therapies and Approaches
`
`Conventional therapy for PAH has included oral
`anticoagulation, supplemental oxygen, diuretics, and
`digoxin, although their use has not been evaluated in
`randomized controlled clinical studies. Microscopic
`thrombi have been observed in postmortem lung tis-
`sue of patients with idiopathic PAH (Fuster et al.,
`1984), and idiopathic PAH has been associated with a
`hypercoagulable state (Tournier et al., 2010). Al-
`though benefits of anticoagulation use have been re-
`ported mainly in those with idiopathic PAH and PAH
`associated with anorexigen use, and observational stud-
`ies have led to conflicting conclusions (Johnson et al.,
`2012), long-term anticoagulation is believed to improve
`survival (Frank et al., 1997; Johnson et al., 2006). Hyp-
`oxia is a potent vasoconstrictor of the pulmonary vascu-
`lature, and supplemental oxygen is recommended to
`maintain oxygen saturation greater than 92% during
`sleep; ambulatory oxygen may benefit those with cor-
`rectable desaturation on exercise (Galié et al., 2009b).
`Calcium-channel blockade is very effective in some
`patients with PAH who respond favorably with acute
`vasodilator testing using epoprostenol or inhaled NO
`[e.g., decrease in mean pulmonary artery pressure
`(mPAP) of at least 10 mm Hg to a nadir £40 mm Hg
`with no clinically significant decrease in cardiac output]
`(Barst et al., 2009). Most acute responders have been
`observed among those with idiopathic or heritable PAH;
`Overall, appr0ximately 8% of adults with idiopathic or
`heritable PAH respond favorably to acute vasodilator
`testing. Recommended calcium channel blockers for
`PAH are limited to nifedipine, amlodipine, and dilti-
`
`azem; verapamil is not used because of its potential for
`negative inotropy (Young et al., 1983; Packer at al.,
`1984). In the absence of acute vasodilator testing, cal-
`cium channel blockers should not be used empirically in
`patients with PAH (Barst et al., 2009).
`Patients not responding to medical therapy may be
`candidates for atr

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket